Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.78 |
| ▸ | RXRB | P28702 | 14/20 | 0.78 |
| ▸ | RXRG | P48443 | 14/20 | 0.78 |
| ▸ | RARA | P10276 | 2/20 | 0.42 |
| ▸ | RARB | P10826 | 2/20 | 0.42 |
| ▸ | RARG | P13631 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049100 | 0.88 | RXRA (1.00) | RXRARXRBRXRGRARARARB | |
| SCHEMBL20411364 | 0.87 | RXRA (0.77) | RXRARXRBRXRGRARARARB | |
| SCHEMBL20411350 | 0.86 | RXRA (0.77) | RXRARXRBRXRGRARARARB | |
| SCHEMBL20411354 | 0.85 | RXRA (0.76) | RXRARXRBRXRGRARARARB | |
| SCHEMBL20411349 | 0.84 | RXRA (0.76) | RXRARXRBRXRGPPARG | |
| SCHEMBL17049092 | 0.77 | RXRA (0.79) | RXRARXRBRXRGRARARARB | |
| SCHEMBL17053967 | 0.76 | RXRA (0.77) | RXRARXRBRXRGRARARARB | |
| SCHEMBL20411359 | 0.74 | RXRA (0.78) | RXRARXRBRXRGRARARARB | |
| SCHEMBL20411355 | 0.73 | RXRA (0.78) | RXRARXRBRXRGRARARARB | |
| SCHEMBL20411344 | 0.73 | RXRA (0.76) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10231947-B2 | Isochroman compounds and methods of use thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180207125-A1 | ISOCHROMAN COMPOUNDS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-07-26 | — | — | US | disclosed |
| US-20180207125-A1 | ISOCHROMAN COMPOUNDS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10231947-B2 | Isochroman compounds and methods of use thereof | MAG, IDH3A, IPO5 | RXRA 2102/4885RXRB 2464/4885RXRG 2174/4885 |
| US-20180207125-A1 | ISOCHROMAN COMPOUNDS AND METHODS OF USE THEREOF | MAG, IDH3A, IPO5 | RXRA 2102/4885RXRB 2464/4885RXRG 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.